Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy (Q44844478)

From Wikidata

Jump to navigation Jump to search

scientific article published on 11 September 2012

Language	Label	Description	Also known as
English	Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy	scientific article published on 11 September 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Nikolaus Kohles

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Dorothea Nagel

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Dietrich Jüngst

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Petra Stieber

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Stefan Holdenrieder

5

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

publication date

11 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

2401-2409

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Estimating the world cancer burden: Globocan 2000.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Diagnosis and Treatment of Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Chemoembolization for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Imaging features of hepatocellular carcinoma after transcatheter arterial chemoembolization and radiofrequency ablation.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Apoptotic markers in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

HMGB1 and RAGE in inflammation and cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Apoptotic DNA fragmentation and tissue homeostasis

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

HMGB1 loves company

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Molecular characteristics of immunogenic cancer cell death.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

High mobility group box 1 protein interacts with multiple Toll-like receptors

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Immunogenic cell death modalities and their impact on cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Immunological aspects of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

High-mobility group box 1 and cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Targeted therapies for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

The expression of HMGB1 protein and its receptor RAGE in human malignant tumors

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0504-2

21 January 2018

Clinical use of circulating nucleosomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nucleosomes in serum of patients with benign and malignant diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of plasma nucleosome levels in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of serum alkaline DNase activity in treatment monitoring of head and neck cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic therapy for advanced hepatocellular carcinoma: past, present, and future

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methodological and preanalytical evaluation of an HMGB1 immunoassay

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methodological and preanalytical evaluation of a RAGE immunoassay

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S13277-012-0504-2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44844478&oldid=2206955210"